---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-219395"
form_type: "8-K"
ticker: "VRCA"
cik: "0001660334"
company_name: "Verrica Pharmaceuticals Inc."
filed_at: "2026-05-12T20:07:19+00:00"
generated_at: "2026-05-12T21:25:42.116039+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Verrica Q1 2026: Net revenue $5.0M; YCANTH units up 51% YoY; net loss $9.7M

## Summary
- YCANTH dispensed units 15,302 (+12.1% QoQ, +51.3% YoY); net product revenue $4.3M (+16.2% QoQ, +25.4% YoY).
- Total revenue $5.0M includes $0.7M license/collaboration revenue from Torii Japan launch.
- Net loss $9.7M ($0.45 per share); non-GAAP net loss $8.8M ($0.41 per share).
- Phase 3 common warts trial (COVE-2) >50% enrolled; second trial (COVE-3) expected mid-2026.
- Appointed Chris Chapman as Chief Commercial Officer; Phase 2 VP-315 BCC data to be presented at SID May 13-16.

## SEC filing metadata
- accession: 0001193125-26-219395
- form_type: 8-K
- ticker: VRCA
- cik: 0001660334
- company_name: Verrica Pharmaceuticals Inc.
- filed_at: 2026-05-12T20:07:19+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1660334/000119312526219395/0001193125-26-219395-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1660334/000119312526219395/d152529d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-219395
- JSON: https://secwatch.observer/filing/0001193125-26-219395.json
- Plain text: https://secwatch.observer/filing/0001193125-26-219395.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.